AnGes Inc(AJW)

Description: AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of ischemic diseases. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and asthma; medical devices for the prevention of vascular medicine; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.

---

Keywords: Biopharmaceutical Disease Inflammation Gene Therapy Vaccines Asthma Atopic Dermatitis Dermatitis Cervical Cancer Back Pain High Blood Pressure Type I Hypersensitivity Atopy Cervical Intraepithelial Neoplasia Hepatocyte Growth Factor Osaka University Gene Based Medical Products Intraepithelial Neoplasia

---

Home Page: www.anges.co.jp

Saito Bio-Incubator
Ibaraki, 567-0085
Japan
Phone:

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)